Trial Profile
A Phase II study evaluating intermittent letrozole as adjuvant endocrine therapy for postmenopausal women with hormone-receptor positive, early stage breast cancer.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Apr 2012
Price :
$35
*
At a glance
- Drugs Letrozole (Primary)
- Indications Early breast cancer
- Focus Biomarker; Therapeutic Use
- 11 Jul 2011 New trial record